WO2021172925A1 - Apoe4 rna 특이적 트랜스-스플라이싱 리보자임 및 이의 용도 - Google Patents
Apoe4 rna 특이적 트랜스-스플라이싱 리보자임 및 이의 용도 Download PDFInfo
- Publication number
- WO2021172925A1 WO2021172925A1 PCT/KR2021/002443 KR2021002443W WO2021172925A1 WO 2021172925 A1 WO2021172925 A1 WO 2021172925A1 KR 2021002443 W KR2021002443 W KR 2021002443W WO 2021172925 A1 WO2021172925 A1 WO 2021172925A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- trans
- ribozyme
- region
- splicing
- rna
- Prior art date
Links
- 0 C1CC*CC1 Chemical compound C1CC*CC1 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Definitions
- the present invention relates to an APOE4 gene-specific trans-splicing ribozyme and uses thereof.
- Alzheimer's disease is one of the main causes of dementia, a degenerative brain disease in which abnormal proteins such as amyloid beta protein and tau protein accumulate in the brain and gradually damage brain neurons. Memory and cognitive functions gradually decline, and as it progresses further, speech and gait disorders appear, making it difficult to live alone.
- APP amyloid precursor protein
- BACE beta-site amyloid precursor protein cleaving enzyme
- amyloid hypothesis Due to the amyloid hypothesis, most Alzheimer's disease candidates are focused on 'inhibiting BACE1' and 'inhibiting the formation of amyloid beta fibrils'.
- Lilly's solanezumab an antibody targeting amyloid beta, failed in phase 3 clinical trials in patients with mild dementia. .
- the amyloid hypothesis which was thought to be the cause of Alzheimer's disease, is being shaken, and there is an argument that the target molecule or the approach must be changed for the treatment of Alzheimer's disease.
- ApoE (Apolipoprotein E) is a protein expressed in the liver and brain, and a number of research results supporting the relationship between ApoE protein expressed in the brain and Alzheimer's have been recently presented. It is known that ApoE protein has two forms of ApoE2, ApoE3, and ApoE4, ApoE2 functions to protect neurons, and ApoE4 contributes to the accumulation of beta-amyloid and exhibits neurotoxicity by itself. In addition, as a result of statistical analysis based on metagenome studies, it was found that APOE4 is a genetic factor that causes Alzheimer's disease. Therefore, an attempt to block the function of ApoE4 for the treatment of Alzheimer's disease is in progress, but the situation is still insufficient.
- ApoE3 christchurch (ApoE3 ch ) mutation is a mutant form of ApoE3 found in elderly people in their 70s, and it has been found that amyloid plaques are found throughout the brain in people with this mutation, but cognitive impairment does not occur ( Nature medicine 2019;11:1680-1683.).
- a group I intron ribozyme from Tetrahmena thermophila targets and attaches an exon RNA attached to the 3' end of the ribozyme in a trans to the 5' exon, thereby linking with a separate transcript. It has been reported that trans-splicing reactions can occur. This suggests that the trans-splicing reaction of group I ribozymes can also correct the transcriptome of genes related to various genetic diseases. It has been found that the ⁇ -globin gene transcript can be converted into an anti-sickling, ⁇ -globin gene transcript by trans-splicing ribozymes in precursor) cells.
- trans-splicing ribozyme can correct mutant gene RNA to normal RNA, and in the same way, it can reduce the expression of a specific gene and simultaneously express a target gene in a host cell.
- the ribozyme operates at the RNA level, there is an advantage in that it does not cause an undesirable immune response problem and safety problem due to the incorporation of a gene at a random location in the host cell genome.
- the present inventors have intensively studied a method for treating Alzheimer's disease using a trans-splicing ribozyme targeting APOE4 and completed the present invention.
- An object of the present invention is to solve the above problems, and an object of the present invention is to provide an Alzheimer's disease-specific trans-splicing ribozyme having excellent safety and expression efficiency and a use for treating Alzheimer's disease using the same.
- the present invention provides a trans-splicing ribozyme that targets APOE4 RNA.
- the trans-splicing ribozyme may have a structure of 5'-IGS (internal guide sequence)-Ribozyme * -exon-3'.
- the IGS region may be composed of a nucleotide sequence of 5 to 10 nt in length that can specifically bind to the 5' UTR region of APOE4 RNA and form a G/U wobble base pair,
- a nucleotide sequence of 5 to 10 nt in length that can specifically bind to the 5' UTR region of APOE4 RNA and form a G/U wobble base pair
- +21, +30, +49, +56, +71, +77, +80, +82, +95, +98, +104, +128, +140, +181, + of APOE4 RNA 229, +255, +263, +275, +326, +368, +830, or +839 position preferably binds complementary to a region comprising position +21, +30, or +56 and binds G/ It may consist of a nucleotide sequence of 5 to 10 nt in length that can form a U wobble base pair.
- the IGS region may include or consist of the nucleotide sequence of SEQ ID NO: 2, 4, or 6.
- the trans-splicing ribozyme may further include an antisense sequence (AS) region capable of complementary binding to a portion of the APOE4 gene upstream of the IGS region.
- AS antisense sequence
- the length of the AS region may be 10 nt to 200 nt, preferably 50 nt to 150 nt.
- the trans-splicing ribozyme may include an IGS region consisting of SEQ ID NO: 2 and an AS region having a length of 150 nt.
- the trans-splicing ribozyme may include an IGS region consisting of SEQ ID NO: 4 and an AS region having a length of 50 nt.
- 5 to 10 random nucleotides may be included between the IGS region and the AS region, and the random nucleotide sequence may be a restriction enzyme sequence, and the random nucleotide sequence is preferably 6 nt in length. It may be composed of a sequence complementary to a part of P1 and P10 illustrated in FIG. 10 .
- the Ribozyme * region may include or consist of the nucleotide sequence of SEQ ID NO: 7.
- the exon region may be a gene for preventing or treating Alzheimer's disease, and may include a part or all of the nucleotide sequence encoding the ApoE2 or ApoE3 christchurch mutation (R136S).
- the present invention provides a trans-splicing ribozyme expression vector comprising a base sequence of the trans-splice ribozyme and/or a base sequence complementary thereto.
- the expression vector may further include a promoter operably linked to the ribozyme gene, and the promoter may be a neuron-specific promoter, and the neuron is a neuron. , astrocytes, and oligodendrocytes.
- the present invention provides a gene delivery system comprising the trans-splicing ribozyme expression vector.
- the present invention is the trans-splicing ribozyme, a vector capable of expressing the same, and Alzheimer's disease prevention or treatment comprising any one or more selected from the group consisting of a gene delivery system comprising the vector as an active ingredient
- a pharmaceutical composition for use is provided.
- the present invention is Alzheimer's disease comprising administering to an individual any one or more selected from the group consisting of the trans-splicing ribozyme, a vector capable of expressing the same, and a gene delivery system comprising the vector A method of preventing or treating is provided.
- the subject may be a human in need of prevention or treatment of Alzheimer's disease, more specifically, an Alzheimer's disease patient, an elderly person (over 60 years of age), or an APOE4 allele carrier.
- the method may further comprise measuring the degree of cognitive ability of the subject.
- the present invention provides the use of the trans-splicing ribozyme, a vector capable of expressing the same, or a gene delivery system comprising the vector for the manufacture of a medicament for preventing or treating Alzheimer's disease.
- the Alzheimer's disease is a neurodegenerative disease in which brain neurons are gradually damaged as abnormal proteins such as amyloid beta protein and tau protein accumulate in the brain, and other diseases appearing as Alzheimer's disease progresses, for example, Alzheimer's dementia include disease.
- the trans-splicing ribozyme according to the present invention replaces RNA of a gene that causes or increases the risk of Alzheimer's disease with RNA of a gene beneficial for disease treatment, thereby lowering the expression of genes causing or increasing the risk of disease , it can be usefully used for the prevention or treatment of Alzheimer's disease because it increases the expression of a gene useful for disease treatment specifically in cells or tissues expressing the target gene.
- FIG. 1 is a schematic diagram of the mechanism of action of a trans-splicing ribozyme targeting APOE4 RNA (FIG. 1a), and a diagram of the result of comparing the sequences of ApoE RNA variants to construct a trans-splicing ribozyme for ApoE4 RNA targeting is (Fig. 1b).
- Figure 2 is a schematic diagram showing the trans-splicing ribozyme for ApoE4 RNA target of the present invention.
- Figure 4 confirms the effect of the AS region on trans-splicing efficiency
- A shows a structure in which the AS region is introduced at the 5' end of the trans-splicing ribozyme for ApoE RNA target
- B is the AS region It is a graph confirming the trans-splicing efficiency of the ribozyme according to the introduction and the length of the introduced AS region.
- FIG. 5 is a view confirming the +56 targeting ribozyme trans-splicing efficiency according to the introduction of the AS region and the length of the introduced AS region in a neuron-derived cell line
- FIG. 5a is a view confirmed at the protein level
- FIG. 5b (A) is a view confirmed at the protein level
- FIG. 5B (B) is a sequencing result of the trans-splicing product.
- FIG. 6 is a schematic diagram and results of an APOE4 RNA reaction site mapping experiment in vitro.
- Figure 7 is a schematic diagram of the reaction site mapping experiment of APOE4 RNA in cells and the results.
- FIG. 8 is a view confirming the trans-splicing efficiency of ribozymes with different target positions of APOE4 RNA.
- Figure 9 is a view confirming the +21 targeting ribozyme trans-splicing efficiency according to the introduction of the AS region and the length of the introduced AS region
- Figure 9a is a view confirmed at the protein level
- Figure 9b is a view confirmed at the gene level
- 9C is a sequencing result of a trans splicing product.
- Figure 10 is a schematic diagram of the structure of the trans-splicing ribozyme of the present invention
- Figure 10a shows the structure of +21 targeting ribozyme
- Figure 10b shows the structure of +30 targeting ribozyme
- Figure 10c is the structure of +56 targeting ribozyme indicates Upstream of the IGS region of each ribozyme may include a three nucleotide region (P1) complementary to APOE4 RNA to increase the binding specificity and binding force of the ribozyme with the target.
- P1 nucleotide region
- each ribozyme includes a 5' region including the P1 region at a position downstream of the ribozyme * region and a P10 region with a length of 5 to 10 nt complementary to the ribozyme trans-splicing as shown in FIG. 10 .
- efficiency can be increased.
- +21 targeting ribozyme consists of SEQ ID NO: 8
- +30 targeting ribozyme consists of SEQ ID NO: 9
- +56 targeting ribozyme consists of or contains the nucleotide sequence of SEQ ID NO: 10 may be doing
- the present inventors studied the cytotoxicity and beta-amyloid accumulation function of the APOE4 protein itself and the gene therapy method for the prevention and treatment of Alzheimer's disease targeting APOE4 from the statistical results of many APOE4 allele carriers among Alzheimer's disease patients. A trans-splicing ribozyme targeting the was completed.
- the present inventors confirmed the consensus sequence in the 5'-UTR region through sequencing of various APOE RNA variants, and set the region including base +56 of APOE4 RNA as a target.
- a trans-splicing ribozyme (+56 targeting ribozyme) including an internal guide sequence (IGS) complementary to the target region was designed (Example 1) , It was confirmed that the +56 targeting ribozyme accurately trans-splices at the desired position of APOE4 RNA (Examples 2 and 3).
- the present inventors introduced an antisense (AS) region having a sequence complementary to APOE RNA at the 5' end of the ribozyme in order to increase the target specificity and trans-splicing efficiency of the +56 targeting ribozyme, and lucifer in the 3' exon region.
- the degree of trans-splicing activity was confirmed by measuring luciferase activity by introducing the lyase gene. As a result, it was found that the introduction of the AS region and the length of the introduced AS region affect the trans-splicing efficiency of the ribozyme (Example 3-1).
- the present inventors confirmed the reaction site through sequencing of the transsplicing product generated by mixing APOE4 RNA and random library ribozyme to secure a target region other than the +56 base of APOE4 RNA, and each reaction site As a result of confirming the trans-splicing effect of the ribozyme targeting .
- the trans-splicing efficiency of ribozymes targeting +21 and +30 of APOE4 RNA was excellent (Example 4).
- the present inventors found that in the ribozyme targeting APOE4 RNA, the target site preferably includes bases +21, +30, and +56, and an IGS sequence of 5-10 nt in length complementary to the region It can be seen that by including the APOE4 RNA-specific efficient trans-splicing can occur.
- the AS region of the sequence complementary to APOE4 RNA is included in the upstream of the IGS region, trans-splicing efficiency can be increased, but the optimal AS region for increasing efficiency It can be seen that the length is different depending on the target site (target base) and the target cell.
- the present inventors provide a trans-splicing ribozyme for reducing the expression of APOE4 protein in neurons in particular for the prevention and treatment of Alzheimer's disease, and the ribozyme is 5'-IGS (internal guide sequence)-Ribozyme * -exon (exon) ) -3' or 5'-AS (antisense) - IGS - Ribozyme * - may have a structure of exon -3'.
- ribozyme refers to an RNA molecule that acts like an enzyme or a molecule composed of a protein containing the RNA molecule, also called RNA enzyme or catalytic RNA. It is an RNA molecule with a clear tertiary structure that performs a chemical reaction and has catalytic or autocatalytic properties. It is known that some ribozymes inhibit the activity by cleaving self or other RNA molecules, and other ribozymes catalyze the aminotransferase activity of ribosomes. Such ribozymes may include hammerhead ribozymes, VS ribozymes and hairpin ribozymes.
- trans-splicing refers to linking RNAs from different genes to each other.
- the ribozyme cuts APOE4 RNA and replaces it with self RNA (particularly, the 3' exon region of the ribozyme) to inhibit the expression of APOE4 protein in the host cell and induce the expression of the gene encoded in the exon region.
- -me ans a splicing ribozyme.
- the ribozyme may have a 5'-IGS (internal guide sequence)-Ribozyme * -exon-3' or 5'-AS (antisense) -IGS-Ribozyme * -exon-3' structure.
- Ribozyme * region in the structure means a region that performs the function of cleavage of APOE4 RNA and/or substitution with an exon region in the trans-splicing ribozyme, and includes or consists of the nucleotide sequence of SEQ ID NO: 7 can
- ribozyme refers to a trans-splicing ribozyme including the entire structure including the ribozyme * region, which is a substantially functional region.
- the gene encoded in the 3' exon region of the ribozyme may be a gene encoding a known protein (or peptide) known to have neuroprotective activity, preferably the APOE2 or APOE3 christchurch gene.
- vector refers to an expression vector capable of expressing a trans-splicing ribozyme in a suitable host cell, and a gene construct comprising essential regulatory elements operably linked to express the ribozyme gene insert contained in the vector.
- operably linked refers to a nucleic acid expression control sequence performing a general function and a nucleic acid sequence encoding a desired gene are functionally linked.
- operably linking a ribozyme coding sequence to a promoter places expression of the ribozyme coding sequence under the influence or control of the promoter.
- Two nucleic acid sequences (a ribozyme coding sequence and a promoter region sequence at the 5' end of the sequence) are operably linked when promoter action is induced and the ribozyme coding sequence is transcribed, and the linkage property between the two sequences is frame-altered. If the mutation (frameshift mutation) does not induce and the expression control sequence does not inhibit the expression of the ribozyme, it can be considered to be operably linked.
- the operable linkage with the recombinant vector may be prepared using genetic recombination techniques well known in the art, and site-specific DNA cleavage and ligation may use enzymes generally known in the art.
- the vector according to the present invention includes a signal sequence or leader sequence for membrane targeting or secretion in addition to expression control elements such as a promoter, operator, initiation codon, stop codon, polyadenylation signal, and enhancer, and may be prepared in various ways depending on the purpose. have.
- the promoter of the vector may be constitutive or inducible.
- the expression vector contains a selectable marker for selecting host cells containing the vector, and in the case of a replicable expression vector, it may contain an origin of replication. Vectors can be self-replicating or integrated into host DNA.
- the vector according to the present invention may be preferably a plasmid vector, a cosmid vector or a viral vector, and most preferably a viral vector.
- the viral vector is preferably a retrovirus, for example, Human immunodeficiency virus (HIV), Murine leukemia virus (MLV), Avian sarcoma/leucosis virus, ASLV), spleen necrosis virus (SNV), Rous sarcoma virus (RSV), mouse mammary tumor virus (MMTV), etc., adenovirus, adeno-associated virus It may be a vector derived from (Adeno-associated virus, AAV), or herpes simplex virus (HSV), but is not limited thereto.
- the recombinant vector according to the present invention may most preferably be a recombinant adeno-associated viral vector.
- promoter is involved in the binding of RNA polymerase to initiate transcription as a part of DNA.
- a transcription factor which is an RNA polymerase or a protein that induces RNA polymerase, to induce the enzyme or protein to be located at the correct transcription start site.
- a transcription factor which is an RNA polymerase or a protein that induces RNA polymerase, to induce the enzyme or protein to be located at the correct transcription start site.
- it is located at the 5' region of the gene to be transcribed on the sense strand and induces RNA polymerase to bind to the position directly or through transcription factors to initiate mRNA synthesis for the target gene.
- the promoter according to the present invention may be a neural cell type-specific promoter from the viewpoint of increasing gene expression in neurons, and the neurons include neurons, astrocytes, and oligodendrocytes.
- gene delivery system refers to a system capable of increasing the expression efficiency by increasing the delivery efficiency of a ribozyme gene and/or nucleic acid sequence into a cell, and a virus-mediated system and a non-viral system. can be classified as
- the virus-mediated system uses viral vectors such as retroviral vectors, adenoviral vectors, and adeno-associated viral vectors, and uses the unique intracellular penetration mechanism of viruses that cause infection in human cells. It is known that the efficiency is relatively high.
- the non-viral vector after entering the cell has a problem in that the endosome is fused with the lysosome and then the genes are degraded in the endolysosome. It has the advantage of high gene transfer efficiency due to its small size.
- Viral vectors that can be used in the present invention may be vectors derived from retroviruses, adenoviruses, adeno-associated viruses, etc. as described in the above recombinant vector.
- a viral vector can be introduced into the cell by a transduction method such as infection (infection) after assembly into the viral particles.
- the non-viral system is a method of using a cationic lipid carrier or a cationic polymer carrier as a delivery medium for nucleic acids and/or genes, or using an electroporation method.
- the cationic lipid delivery system uses the positive charge of nanometer-sized liposomes or lipid material nanoparticles mainly composed of cationic lipids to form a complex with a negatively charged gene, an expression vector or a nucleic acid containing the gene, and then converts the complex into phagocytosis.
- a method of delivery into cells The complex delivered into the cell is first delivered from the endosome to the lysosome, and then exits into the cytoplasm and is expressed.
- Cationic polymer delivery systems deliver genes in a similar manner to cationic lipid delivery systems except that polymers are used instead of lipids.
- Representative cationic polymers include polyethyleneimine, poly-L-lysine, and chitosan. (chitosan), etc.
- the complex formed by combining the recombinant vector of the present invention with a cationic lipid carrier or a cationic polymer carrier can be used as a gene carrier.
- the gene delivery system includes the above-described recombinant vector, and both a virus-mediated system and a non-viral system may be used, but a virus-mediated system is preferably used.
- the trans-splicing ribozyme of the present invention can inhibit APOE4 protein expression by targeting APOE4 RNA in neurons, and APOE4 is known as a major risk-inducing gene for Alzheimer's disease.
- APOE4 is known as a major risk-inducing gene for Alzheimer's disease.
- a splicing ribozyme, the ribozyme expression vector, and a gene delivery system comprising the vector can be used in a pharmaceutical composition for preventing or treating Alzheimer's disease.
- prevention refers to any action of inhibiting or delaying the onset of Alzheimer's disease by administering the pharmaceutical composition according to the present invention.
- treatment refers to any action that improves Alzheimer's disease or changes its symptoms beneficially by administration of a composition containing the vector according to the present invention.
- the pharmaceutical composition according to the present invention may further include a pharmaceutically acceptable carrier, excipient or diluent.
- pharmaceutically acceptable carriers, excipients and diluents that can be used in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate. , gelatin, calcium phosphate, calcium silicate, calcium carbonate, cellulose, methyl cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, and the like.
- the pharmaceutical composition of the present invention may be administered orally or parenterally according to a desired method, but is preferably administered parenterally.
- the pharmaceutical composition according to the present invention may be administered intravenously, intraarterially, intracerebral tissue, subcutaneous administration or intracisternal injection.
- the injection according to the present invention may be in a form dispersed in a sterile medium so that it can be used as it is when administered to a patient, or may be administered after dispersing it at an appropriate concentration by adding distilled water for injection during administration.
- it when prepared as an injection, it may be mixed with a buffer, preservative, analgesic agent, solubilizer, isotonic agent, stabilizer, etc., and may be prepared in a unit dosage ampule or multiple dosage form.
- the dosage of the pharmaceutical composition of the present invention varies depending on the condition and weight of the patient, the degree of disease, the drug form, the route and time of administration, but may be appropriately selected by those skilled in the art. Meanwhile, the pharmaceutical composition according to the present invention may be used alone or in combination with other Alzheimer's therapeutic agents or treatment methods.
- RNA variants V1 to V5 published in NCBI were compared, and a ribozyme and GU wobble base pair among the consensus sequence (23 bp) of 5'-UTR was selected.
- the target site includes the base at position +56 of APOE4 RNA (SEQ ID NO: 11), and IGS (GUUCCG: SEQ ID NO: 2) capable of targeting the target site at the 5' end and the 3' end of the target
- a trans-splicing ribozyme hereinafter, referred to as '+56 targeting ribozyme'
- FIG. 2 A trans-splicing ribozyme (hereinafter, referred to as '+56 targeting ribozyme') targeting ApoE4 RNA into which the gene ApoE2 was introduced was constructed (FIG. 2).
- the +56 targeting ribozyme was cloned into a pcDNA vector to prepare a vector for trans-splicing ribozyme expression.
- RNA product after the reaction was recovered by phenol extraction/ethanol precipitation method and dissolved in 10 ⁇ l of distilled water (D.W) treated with DEPC (diethyl pyrocarbonate).
- an antisense (AS) region having a sequence complementary to APOE4 RNA was introduced at the 5' end of the ribozyme.
- a luciferase gene was introduced into the 3' exon region of the ribozyme in order to confirm trans-splicing efficiency according to the length of the AS region. Luciferase activity was measured when the length of the AS region was 0 nt, 50 nt, 100 nt, or 150 nt.
- each ribozyme expression vector was transfected into the Huh-7.5 cell line expressing ApoE and the 293A cell line not expressing it, and a luciferase assay was performed.
- the trans-splicing efficiency of the trans-splice ribozyme introduced with 50 antisense sequences was remarkably excellent, but in the 293A cell line, the trans-splicing of each ribozyme was It was confirmed that there was no significant difference in the efficiency (FIG. 4B).
- the trans-splicing ribozyme should be able to effectively trans-splice in neurons to reduce APOE4 gene expression. Accordingly, the experiment of Example 3-1 was repeated in a neuron-derived cell line, and the trans-splicing efficiency according to the length of the AS region was confirmed.
- 1x10 5 CCF-STTG1 (E3/E4, astrocyte) cells were cultured in a 12 well plate for 24 hours, and +56 containing AS regions of different lengths (0nt, 50nt, 100nt, or 150nt) 500ng of a plasmid vector expressing a targeting ribozyme and 50ng of a pTK-renilla luciferase plasmid vector were co-transfected for 48 hours.
- transsplicing of APOE4 RNA was induced by ribozyme in CCF-STTG1 cells regardless of the presence or absence of the AS region and the length of the AS region. It was confirmed that the trans-splicing efficiency by the zyme was excellent (FIG. 5a).
- electrophoresis was performed to detect a trans-splicing product. More specifically, 2x10 5 CCF-STTG1 or U118MG (E2/E4) cells were cultured in a 6 well plate for 24 hours, and transformation was induced with 2.5ug of +56 targeting ribozyme expression vector. After 48 hours, all of the culture medium was removed, washed once with 1 mL of 1xPBS, and the cells recovered and 100uL of chloroform were mixed to extract total RNA. After adding RT primer (5'-CCCATATCGTTTCATAGCTTCTGCC-3') to 1ug of the extracted total RNA, reverse transcription was performed under 20uL volume conditions to generate cDNA.
- RT primer 5'-CCCATATCGTTTCATAGCTTCTGCC-3'
- 2uL of the cDNA was mixed with a forward primer (5'-CAGCGGAGGTGAAGGACGT-3') and a reverse primer (5'-ATGTTCACCTCGATATGTGCATC-3') and subjected to 30 cycle PCR under the conditions of 95 °C 30 sec, 58 °C 30 sec, 72 °C 30 sec. and confirmed the PCR band on 2% TBE agarose gel.
- a forward primer 5'-CAGCGGAGGTGAAGGACGT-3'
- a reverse primer 5'-ATGTTCACCTCGATATGTGCATC-3'
- APOE4 RNA and random library ribozyme were mixed and reacted in a test tube, followed by RT-PCR. Sequence analysis of PCR DNA band expected as a transsplicing product The APOE4 RNA site where trans-splicing occurred was confirmed.
- APOE4 RNA was synthesized through the in-vitro transcription process, and a trans-splicing ribozyme RNA library having a random sequence (GNNNNN) at the 5' end was synthesized through the in vitro transcription process.
- trans-splicing ribozyme targeting the +21 base of APOE4 RNA (hereinafter referred to as '+21 targeting ribozyme') is effective in reducing APOE4 protein expression.
- +30, +71, +77, +80, and +82 sites identified as overlapping and +21 sites with the highest transsplicing frequency for in vitro mapping were selected.
- a ribozyme targeting each site was prepared, and trans-splicing was confirmed by performing an in vitro trans-splicing reaction.
- +56 targeting ribozyme was used as a control.
- APOE4 RNA was mixed with 1 pmole of each trans-splicing ribozyme library RNA to induce a trans-splicing reaction.
- RNA was recovered from each reaction solution, RT-PCR was performed, and the prepared cDNA was used with APOE4 RNA specific 5' primer (5'-CTACTCAGCCCCAGCGGAGG-3') and ribozyme specific 3' primer (5'-TGTAAAAACGACGGCCAGTG-3') and PCR amplification (95 °C 30 sec, 55 °C 30 sec, 72 °C 30 sec, 35 cycle), and each amplified product was confirmed by electrophoresis on agarose gel.
- the target region including the +21 base is 5'-GGAGGU-3' (SEQ ID NO: 3), and the IGS of the +21 targeting ribozyme has 5'-GCCUCC-3' (SEQ ID NO: 4).
- the target region including base +30 in APOE4 RNA is 5'-GGACGU-3' (SEQ ID NO: 5), and the IGS of +30 targeting ribozyme has 5'-GCGUCC-3' (SEQ ID NO: 6).
- a ribozyme introduced with an AS region having a different length as in Example 3 was prepared. After transformation into Huh-7.5 cells, CCF-STTG1 cells, and U118MG cells, the degree of trans-splicing was confirmed at the protein level and gene level.
- the ribozyme targeting the +21 base of APOE4 RNA induced transsplicing of APOE4 RNA in cells expressing APOE4 regardless of whether the AS region was introduced or the length of the AS region. It was confirmed that the trans-splicing efficiency was remarkably excellent in the ribozyme into which the 50 nt-length AS region was introduced (FIG. 9a).
- the trans-splicing product confirmation result was the same as the protein-level confirmation result (FIG. 9b), and it was confirmed that the reaction occurred precisely at the expected trans-splicing position as a result of sequencing of the trans-splicing product (Fig. 9c).
- the APOE4 target trans-splicing ribozyme of the present invention can be used as a drug for the prevention or treatment of Alzheimer's disease by inhibiting the expression of APOE4 protein, which itself increases the incidence of Alzheimer's disease, and by trans-splicing Since it can induce the expression of a gene that lowers the incidence of Alzheimer's disease, it can be used as a platform for introducing a therapeutic gene for Alzheimer's disease.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims (17)
- APOE4 RNA 서열을 표적으로 하는 트랜스-스플라이싱 리보자임.
- 제1항에 있어서,상기 트랜스-스플라이싱 리보자임은 5'- IGS (internal guide sequence)-Ribozyme*-엑손(exon)-3'의 구조를 갖는 것을 특징으로 하는, 트랜스-스플라이싱 리보자임.
- 제2항에 있어서,상기 IGS 영역은 APOE4 RNA의 +21, +30,+49, +56, +71, +77, +80, +82, +95, +98, +104, +128, +140, +181, +229, +255, +263, +275, +326, +368, +830, 또는 +839 염기를 포함하는 영역과 상보적으로 결합할 수 있는 5~10 nt 길이의 염기서열로 이루어진 것을 특징으로 하는, 트랜스-스플라이싱 리보자임.
- 제3항에 있어서,상기 IGS 영역은 서열번호 2, 4, 또는 6의 염기서열을 포함하는 것을 특징으로 하는, 트랜스-스플라이싱 리보자임.
- 제2항에 있어서,상기 트랜스-스플라이싱 리보자임은 IGS 영역의 upstream에 APOE4 RNA의 일부와 상보적으로 결합할 수 있는 10 nt 내지 200 nt 길이의 AS(antisense sequence) 영역을 추가로 포함하는 것을 특징으로 하는, 트랜스-스플라이싱 리보자임.
- 제5항에 있어서,상기 IGS 영역은 서열번호 2의 염기서열을 포함하고, 상기 AS 영역은 150 nt 길이인 것을 특징으로 하는, 트랜스-스플라이싱 리보자임.
- 제5항에 있어서,상기 IGS 영역은 서열번호 4의 염기서열을 포함하고, 상기 AS 영역은 50 nt 길이인 것을 특징으로 하는, 트랜스-스플라이싱 리보자임.
- 제5항에 있어서,상기 IGS 영역과 AS 영역은 5~10 nt 길이의 무작위 염기서열로 연결된 것을 특징으로 하는, 트랜스-스플라이싱 리보자임.
- 제2항에 있어서,상기 Ribozyme* 영역은 서열번호 5의 염기서열을 포함하는 것을 특징으로 하는, 트랜스-스플라이싱 리보자임.
- 제2항에 있어서,상기 엑손 영역은 ApoE2 또는 ApoE3 christchurch 돌연변이(R136S)를 암호화하는 염기서열의 일부 또는 전부를 포함하는 것을 특징으로 하는, 트랜스-스플라이싱 리보자임.
- 제1항 내지 제10항 중 어느 한 항의 트랜스-스플라이싱 리보자임을 발현할 수 있는 발현 벡터.
- 제11항에 있어서,상기 발현 벡터는 상기 리보자임 유전자와 작동가능하게 연결된 프로모터를 추가로 포함하는 것을 특징으로 하는, 발현 벡터.
- 제12항에 있어서,상기 프로모터는 신경세포 타입 특이적인 프로모터인 것을 특징으로 하는, 발현 벡터.
- 제13항에 있어서,상기 신경세포 타입 특이적인 프로모터는 뉴런(neuron)-, 성상세포(astrocyte)- 또는 희돌기교 세포(oligodendrocyte)- 특이적 프로모터인 것을 특징으로 하는, 발현 벡터.
- 제1항 내지 제10항의 트랜스-스플라이싱 리보자임; 제11항 내지 제14항의 발현 벡터; 및 상기 발현 벡터를 포함하는 유전자 전달 시스템;으로 이루어진 군으로부터 선택되는 어느 하나를 유효성분으로 포함하는 알츠하이머 예방 또는 치료용 약학적 조성물.
- 제1항의 트랜스-스플라이싱 리보자임, 이를 발현할 수 있는 벡터, 및 상기 벡터를 포함하는 유전자 전달 시스템으로 이루어진 군으로부터 선택되는 어느 하나 이상을 개체에 투여하는 단계를 포함하는 알츠하이머병 예방 또는 치료 방법.
- 알츠하이머병 예방 또는 치료 약제의 제조를 위한 제1항의 트랜스-스플라이싱 리보자임, 이를 발현할 수 있는 벡터, 또는 상기 벡터를 포함하는 유전자 전달 시스템의 용도.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180004858.3A CN114269925A (zh) | 2020-02-28 | 2021-02-26 | Apoe4 rna特异性反式剪接核酶及其用途 |
EP21760156.6A EP3992292A4 (en) | 2020-02-28 | 2021-02-26 | APOE4 RNA SPECIFIC TRANS-SPLICING RIBOZYME AND USE THEREOF |
AU2021225696A AU2021225696A1 (en) | 2020-02-28 | 2021-02-26 | Trans-splicing ribozyme specific to ApoE4 RNA and use thereof |
JP2022507489A JP2022543446A (ja) | 2020-02-28 | 2021-02-26 | Apoe4 rna特異的トランススプライシングリボザイム及びその用途 |
CA3173742A CA3173742A1 (en) | 2020-02-28 | 2021-02-26 | Trans-splicing ribozyme specific to apoe4 rna and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0025332 | 2020-02-28 | ||
KR20200025332 | 2020-02-28 | ||
KR10-2021-0025822 | 2021-02-25 | ||
KR20210025822 | 2021-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021172925A1 true WO2021172925A1 (ko) | 2021-09-02 |
Family
ID=77490120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/002443 WO2021172925A1 (ko) | 2020-02-28 | 2021-02-26 | Apoe4 rna 특이적 트랜스-스플라이싱 리보자임 및 이의 용도 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3992292A4 (ko) |
JP (1) | JP2022543446A (ko) |
CN (1) | CN114269925A (ko) |
AU (1) | AU2021225696A1 (ko) |
CA (1) | CA3173742A1 (ko) |
WO (1) | WO2021172925A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023078883A1 (en) * | 2021-11-03 | 2023-05-11 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating apolipoprotein e4 expression |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114521214A (zh) * | 2020-07-24 | 2022-05-20 | 尔知渃米斯股份有限公司 | 视紫红质转录体特异性反式剪接核酶及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007530035A (ja) * | 2004-03-22 | 2007-11-01 | バイオアークティック ニューロサイエンス アーベー | アルツハイマー病のためのトランスジェニックモデル |
KR20090118956A (ko) * | 2007-02-06 | 2009-11-18 | 유태준 | 유전자 요법을 사용한 신경퇴행성 질환의 치료 및 예방 |
KR20130118671A (ko) * | 2012-04-20 | 2013-10-30 | 단국대학교 산학협력단 | Aimp2 유전자의 스플라이싱 변이체 특이적인 트랜스-스플라이싱 활성을 갖는 핵산 분자 및 이를 이용한 폐암 치료용 약학 조성물 및 폐암 진단용 조성물 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030069195A1 (en) * | 1996-03-01 | 2003-04-10 | Farrar Gwenyth Jane | Suppression of polymorphic alleles |
CN101321526A (zh) * | 2005-09-22 | 2008-12-10 | Sb药物波多黎各公司 | 用于改善认知功能的罗格列酮和多奈派齐组合物 |
EP1991252A2 (en) * | 2006-02-21 | 2008-11-19 | Oklahoma Medical Research Foundation | Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor |
KR100907106B1 (ko) * | 2007-10-25 | 2009-07-09 | 국립암센터 | 라이보자임을 함유한 아데노바이러스를 이용한 질병의분자영상진단법 |
WO2016126071A1 (ko) * | 2015-02-02 | 2016-08-11 | 단국대학교 산학협력단 | 키메릭 항원 수용체 전달용 ctla-4 타겟팅 트랜스-스플라이싱 라이보자임 및 이의 용도 |
US20190338363A1 (en) * | 2016-12-18 | 2019-11-07 | Selonterra, Inc. | Use of apoe4 motif-mediated genes for diagnosis and treatment of alzheimer's disease |
CN111607610A (zh) * | 2019-02-22 | 2020-09-01 | 尔知诺米斯股份有限公司 | 癌症特异性反式剪接核酶及其用途 |
CN116670172A (zh) * | 2021-01-25 | 2023-08-29 | 尔知渃米斯股份有限公司 | 表达免疫检查点抑制剂的癌症特异性反式剪接核酶及其用途 |
-
2021
- 2021-02-26 WO PCT/KR2021/002443 patent/WO2021172925A1/ko unknown
- 2021-02-26 JP JP2022507489A patent/JP2022543446A/ja active Pending
- 2021-02-26 CN CN202180004858.3A patent/CN114269925A/zh active Pending
- 2021-02-26 CA CA3173742A patent/CA3173742A1/en active Pending
- 2021-02-26 EP EP21760156.6A patent/EP3992292A4/en active Pending
- 2021-02-26 AU AU2021225696A patent/AU2021225696A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007530035A (ja) * | 2004-03-22 | 2007-11-01 | バイオアークティック ニューロサイエンス アーベー | アルツハイマー病のためのトランスジェニックモデル |
KR20090118956A (ko) * | 2007-02-06 | 2009-11-18 | 유태준 | 유전자 요법을 사용한 신경퇴행성 질환의 치료 및 예방 |
KR20130118671A (ko) * | 2012-04-20 | 2013-10-30 | 단국대학교 산학협력단 | Aimp2 유전자의 스플라이싱 변이체 특이적인 트랜스-스플라이싱 활성을 갖는 핵산 분자 및 이를 이용한 폐암 치료용 약학 조성물 및 폐암 진단용 조성물 |
Non-Patent Citations (3)
Title |
---|
JULIA E. LOVE: "Alternative Splicing in Alzheimer’s Disease", JOURNAL OF PARKINSON’S DISEASE AND ALZHEIMER'S DISEASE, vol. 2, no. 2, 2 August 2015 (2015-08-02), XP055335783, DOI: 10.13188/2376-922X.1000010 * |
NATURE MEDICINE, vol. 11, 2019, pages 1680 - 1683 |
See also references of EP3992292A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023078883A1 (en) * | 2021-11-03 | 2023-05-11 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating apolipoprotein e4 expression |
Also Published As
Publication number | Publication date |
---|---|
AU2021225696A1 (en) | 2022-09-29 |
EP3992292A4 (en) | 2023-06-21 |
CN114269925A (zh) | 2022-04-01 |
CA3173742A1 (en) | 2021-09-02 |
EP3992292A1 (en) | 2022-05-04 |
JP2022543446A (ja) | 2022-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230001016A1 (en) | Rna guided eradication of human jc virus and other polyomaviruses | |
JP7176737B2 (ja) | レトロウイルス核酸配列の切除 | |
US11427824B2 (en) | Compositions and methods for the treatment of myotonic dystrophy | |
CN110337493B (zh) | 用于治疗肌强直性营养不良的组合物和方法 | |
WO2021172925A1 (ko) | Apoe4 rna 특이적 트랜스-스플라이싱 리보자임 및 이의 용도 | |
EA037359B1 (ru) | Способы и композиции для рнк-направляемого лечения инфекции, вызываемой вич | |
US20210260168A1 (en) | Compositions and methods of fas inhibition | |
US20210054370A1 (en) | Methods and compositions for treating angelman syndrome | |
CA2251818A1 (en) | Mammalian genes involved in viral infection and tumor suppression | |
KR102315736B1 (ko) | Apoe4 rna 특이적 트랜스-스플라이싱 리보자임 및 이의 용도 | |
JP7393770B2 (ja) | ゲノム編集による2つの最も高頻度に見られるush2a突然変異の修正 | |
US20190071673A1 (en) | CRISPRs WITH IMPROVED SPECIFICITY | |
WO2011162558A2 (ko) | 아데닐레이트 싸이클라제 활성화 폴리펩타이드 1 (뇌하수체)의 유전자를 함유하는 자궁경부암세포의 증식 억제용 재조합벡터 및 자궁경부암 치료용 약학 조성물 | |
US20230119699A1 (en) | Diagnostic methods using sirt1 expression | |
US20230121720A1 (en) | Diagnostic methods using pcg-1a expression | |
US20230220361A1 (en) | Crispr-cas9 mediated disruption of alcam gene inhibits adhesion and trans-endothelial migration of myeloid cells | |
WO2000023084A1 (en) | Methods for stimulating the regeneration of inner ear cells | |
US20240271128A1 (en) | Rna guided eradication of herpes simplex type i and other related human herpesviruses | |
EP3901262A1 (en) | Compositions for use in treating autosomal dominant best1-related retinopathies | |
US20230126157A1 (en) | Mirna-485 inhibitor for gene upregulation | |
Surace et al. | Clarissa Patrizi, Manel Llado, 2 Daniela Benati, Carolina Iodice, 2 Elena Marrocco, 2 Rosellina Guarascio, 3 | |
Kodra | The Role of Chromatin in Olfaction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21760156 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021760156 Country of ref document: EP Effective date: 20220126 |
|
ENP | Entry into the national phase |
Ref document number: 2022507489 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3173742 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021225696 Country of ref document: AU Date of ref document: 20210226 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |